GoodRx Holdings (GDRX) EBITDA (2019 - 2026)

GoodRx Holdings has disclosed EBITDA across 8 years of filings, most recently posting $14.0 million for Q1 2026.

• EBITDA for Q1 2026 came in at $14.0 million, down 40.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $78.1 million (down 4.55% YoY), and the FY2025 annual result was $91.7 million, up 30.34% from the prior year.
• EBITDA came in at $14.0 million for Q1 2026 at GoodRx Holdings, down from $22.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $26.8 million in Q2 2025 to a low of -$38.3 million in Q3 2023.
• The 5-year median for EBITDA is $14.6 million (2025), against an average of $8.4 million.
• Peak annual rise in EBITDA reached 552.38% in 2023, while the deepest fall reached 1152.85% in 2023.
• GoodRx Holdings' EBITDA stood at $1.7 million in 2022, then plunged by 1152.85% to -$18.3 million in 2023, then soared by 199.41% to $18.2 million in 2024, then increased by 24.77% to $22.7 million in 2025, then slumped by 38.24% to $14.0 million in 2026.
• The last three EBITDA figures came in at $14.0 million (Q1 2026), $22.7 million (Q4 2025), and $14.6 million (Q3 2025), per Business Quant data.